Why the study?
Does the choice of dihydropyridine calcium channel blocker formulation (nifedipine retard, nifedipine GITS, or amlodipine) affect circulating catecholamine levels in patients with essential hypertension?
Population
63 patients of both sexes with mild-to-moderate essential hypertension (diastolic blood pressure 95-115 mmHg).
Comparison
Nifedipine retard 10-20 mg twice daily… vs Active comparators.
Design
RCT, randomly allocated
Follow-up
6 weeks
Authors
Loading...
Nifedipine GITS may limit sympathetic activation versus other dihydropyridines; extends evidence on formulation-dependent catecholamine effects in hypertension.
Does the choice of dihydropyridine calcium channel blocker formulation (nifedipine retard, nifedipine GITS, or amlodipine) affect circulating catecholamine levels in patients with essential hypertension?
Different dihydropyridine calcium channel blockers have varying effects on sympathetic activation, with nifedipine GITS showing no increase in norepinephrine compared to nifedipine retard and amlodipine.
Champlain et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: